Cancer Prevention Pharmaceuticals, Inc.

Cancer Prevention Pharmaceuticals, Inc. specializes in innovative solutions aimed at reducing cancer risk, focusing on research and development of pharmaceutical products that address preventive care for various cancer types. Founded in 2008 in Tucson, US, Cancer Prevention Pharmaceuticals, Inc. is dedicated to developing pharmaceuticals that prevent cancer.

Eugene Gerner, the founder, has a background in health and wellness, enhancing the company’s focus on preventive solutions. The company has engaged in 5 deals, with the most recent being a VENTURE DEBT round in June 2022, raising USD 5. 00 mn, bringing the total amount raised to USD 4. 30 mn.

Cancer Prevention Pharmaceuticals provides a comprehensive platform centered around wellness education, emphasizing nutrition, detoxification, immune health, and lifestyle impacts on well-being. Their offerings include educational articles and guides addressing health concerns such as intermittent fasting and the importance of physical activity, targeting a diverse audience across multiple regions, including Indonesia and Southeast Asia. In 2015, Cancer Prevention Pharmaceuticals reported revenue of USD 3,714,603 with an EBITDA of USD -3,916,439, indicating their focus on building a community around health education services. Cancer Prevention Pharmaceuticals plans to enhance its product offerings with new pharmaceutical solutions aimed at preventive care.

Following their recent acquisition by Panbela Therapeutics, Inc. in June 2022, which included USD 60 mn in future milestone and royalty payments, the company intends to leverage this partnership to expand into additional markets. Their strategy focuses on broadening access to their health education resources and developing innovative products that align with their mission of cancer prevention.